RSV typically causes cold-like symptoms, but is also a leading cause of pneumonia in toddlers and older adults. An estimated ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

Johnson & Johnson will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th. Management will participate in a Fireside Chat at 1:35 p.m. Eastern Time. This ...

CDC panel expands RSV vaccine recommendations for at-risk adults aged 50-59, including Pfizer's Abrysvo. Read more here.

Pfizer (PFE) announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

by Timothy McQuiston, Vermont Business Magazine The Vermont Department of Health reported last week that the number of COVID-19 hospitalizations remains low, at under 5 after a spike in January.

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...